Xeris Biopharma Holdings, Inc.

Pharmaceutical Preparations

XERS Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001867096 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$1.36B
182,320,306 shares Covers every share class this company has on file.
Insiders on file
14
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$84.60M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
6.23%
insider-held value divided by market capitalisation

What Xeris Biopharma Holdings, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$291.85M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$554.0K
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
435
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Xeris Biopharma Holdings, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Xeris Biopharma Holdings, Inc..
Insider Reported role Shares Value Last action
Officers 5
Kevin McCulloch Executive 1,802,725 $15.38M S Open-market sale Sep 1, 2026 position reported
Steven Pieper Executive 1,408,940 $12.02M S Open-market sale Sep 1, 2026 position reported
Beth Hecht Executive 1,226,507 $10.46M S Open-market sale Sep 1, 2026 position reported
Anh Tu Nguyen Executive 402,234 $3.43M F Shares withheld for taxes Feb 24, 2026 position reported
Kenneth Erland Johnson Executive 320,446 $2.73M F Shares withheld for taxes Jan 31, 2025 position reported
Officers who also sit on the board 2
John Patrick Shannon Jr. Executive 2,935,578 $25.04M F Shares withheld for taxes Aug 1, 2026 position reported
John Johnson John Johnson Executive Chairman 698,083 $5.95M A Grant or award Jun 4, 2026 position reported
Directors 7
Jeffrey W. Sherman Board Member 224,588 $1.92M S Open-market sale Aug 28, 2025 position reported
Garheng Kong Board Member 214,144 $1.83M A Grant or award Jun 4, 2026 position reported
Marla Persky Board Member 148,370 $1.27M A Grant or award Jun 4, 2026 position reported
Barbara-Jean Anne Bormann-Kennedy Board Member 142,500 $1.22M A Grant or award Jun 4, 2026 position reported
John P Schmid Board Member 138,359 $1.18M P Open-market purchase Aug 12, 2024 position reported
Ricki Louise Fairley Board Member 135,000 $1.15M A Grant or award Jun 5, 2024 position reported
Dawn Halkuff Board Member 120,410 $1.03M A Grant or award Jun 4, 2026 position reported

Recent insider transactions

Of the 151 rows we hold, 4 are open-market purchases (P) and 33 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Xeris Biopharma Holdings, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 1, 2026 Kevin McCulloch S Open-market sale 15,000 $8.49 $127.4K SEC filing ↗
Sep 1, 2026 Steven Pieper S Open-market sale 5,000 $8.50 $42.5K SEC filing ↗
Sep 1, 2026 Beth Hecht S Open-market sale 16,666 $8.49 $141.5K SEC filing ↗
Aug 12, 2026 Steven Pieper S Open-market sale 5,000 $8.50 $42.5K SEC filing ↗
Aug 3, 2026 Kevin McCulloch S Open-market sale 15,000 $8.02 $120.3K SEC filing ↗
Aug 3, 2026 Beth Hecht S Open-market sale 16,666 $8.01 $133.5K SEC filing ↗
Aug 1, 2026 John Patrick Shannon Jr. F Shares withheld for taxes 36,645 $8.08 $296.1K SEC filing ↗
Aug 1, 2026 Kevin McCulloch F Shares withheld for taxes 21,918 $8.08 $177.1K SEC filing ↗
Jul 7, 2026 Steven Pieper S Open-market sale 27,600 $8.52 $235.2K SEC filing ↗
Jul 6, 2026 Steven Pieper S Open-market sale 17,400 $8.50 $147.9K SEC filing ↗
Jul 1, 2026 Kevin McCulloch S Open-market sale 90,000 $8.03 $722.7K SEC filing ↗
Jul 1, 2026 Beth Hecht S Open-market sale 16,666 $8.03 $133.8K SEC filing ↗
Jun 4, 2026 Garheng Kong A Grant or award 24,193 $0.00 $0 SEC filing ↗
Jun 4, 2026 Marla Persky A Grant or award 24,193 $0.00 $0 SEC filing ↗
Jun 4, 2026 Dawn Halkuff A Grant or award 24,193 $0.00 $0 SEC filing ↗
Jun 4, 2026 Dawn Halkuff S Open-market sale 20,000 $6.09 $121.8K SEC filing ↗
Jun 4, 2026 Barbara-Jean Anne Bormann-Kennedy A Grant or award 24,193 $0.00 $0 SEC filing ↗
Jun 4, 2026 Barbara-Jean Anne Bormann-Kennedy S Open-market sale 16,000 $6.09 $97.4K SEC filing ↗
Jun 4, 2026 John Johnson A Grant or award 24,193 $0.00 $0 SEC filing ↗
Jun 4, 2026 John Johnson S Open-market sale 15,000 $6.09 $91.4K SEC filing ↗
Jun 3, 2026 Marla Persky S Open-market sale 15,500 $5.90 $91.5K SEC filing ↗
Jun 1, 2026 Beth Hecht S Open-market sale 16,667 $6.06 $101.0K SEC filing ↗
May 1, 2026 Beth Hecht S Open-market sale 16,667 $6.23 $103.8K SEC filing ↗
Apr 1, 2026 Beth Hecht S Open-market sale 16,667 $5.99 $99.8K SEC filing ↗
Mar 12, 2026 Kevin McCulloch M Option exercise or conversion 4 $3.94 $16 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Subsidiaries — 5 legal entities

Subsidiaries of Xeris Biopharma Holdings, Inc.

5 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Xeris Biopharma Holdings, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Cortendo AB Sweden
Strongbridge Biopharma Limited Ireland
Strongbridge Dublin Limited Ireland
Xeris Pharmaceuticals Australia Pty Ltd Australia
Xeris Pharmaceuticals, Inc. Delaware
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Xeris Biopharma Holdings, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Xeris Biopharma Holdings, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.